ESR1 and breast cancer: Jab1/CSN5 was shown to be a target of EGFR signaling in estrogen receptor-alpha-negative (ERα-) breast cancer and the translocation of Jab1/CSN5 to the nucleus was shown to be mediated through the ERK signaling pathway [98].